Lexchin Joel, Arya Neil, Singh Sonal
Professor, School of Health Policy and Management, York University, Emergency Physician, University Health Network.
Healthc Policy. 2010 May;5(4):26-36.
The federal and provincial governments have undertaken a universal immunization program to protect school-aged girls against cervical cancer using the new human papillomavirus vaccine Gardasil®. While the vaccine appears to be effective and safe, there are a number of important unanswered questions regarding it and the effects of the immunization program. Here we briefly review key literature about the vaccine and then use the Erickson criteria, which offer an evidence basis for decision-making regarding national immunization strategies, to evaluate whether the program is congruent with sound public health policy. Our analysis of the national decision to recommend and fund a vaccination program using Gardasil® raises significant questions about the basis for this program.
联邦和省政府已开展一项通用免疫计划，使用新型人乳头瘤病毒疫苗加德西（Gardasil®）来保护学龄女童预防宫颈癌。虽然该疫苗似乎有效且安全，但关于它以及免疫计划的影响仍有许多重要问题尚未得到解答。在此，我们简要回顾关于该疫苗的关键文献，然后运用埃里克森标准（该标准为国家免疫策略的决策提供了证据基础）来评估该计划是否符合合理的公共卫生政策。我们对国家推荐并资助使用加德西（Gardasil®）的疫苗接种计划这一决策的分析，引发了关于该计划依据的重大问题。
